Iaso Biotherapeuticsalso Known As Iaso Biois A Prominent Biopharmaceutical Company Based In Jiangsuchinawith A Focus On Developing And Commercializing Cell Therapies And Biologicsthe Company Aims To Provide Innovative And Affordable Treatments For Unmet Medical Needsparticularly In Oncology And Autoimmune Diseasesiaso Bio Offers A Wide Range Of Services Throughout The Drug Development Lifecycleutilizing Proprietary Platforms Such As The Innovative Monoclonal Antibody Research Systemimarsand A Car T Drug Screening Platformthe Company Has A Robust Pipeline Featuring Over 10 Novel Productsincluding The Car T Therapy Equecabtagene Autoleucelfucasoand The Anti Cd19 Monoclonal Antibody Iaso 782Both Of Which Have Received Regulatory Approvals In China And The Usa The Company Has Formed Strategic Partnerships With Leading Cell Therapy Firmsenhancing Its Capabilities In Advancing Next Generation Therapiesas Of January 2023Iaso Biotherapeutics Has Raised Over $242 Million In Fundingreflecting Its Strong Position In The Biopharmaceutical Industry
